Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT00478075
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT00477412
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00473590
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 7
- Registration Number
- NCT00464178
- Locations
- 🇺🇸
The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00458705
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00458822
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
- Conditions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2018-07-12
- Target Recruit Count
- 82
- Registration Number
- NCT00458913
- Locations
- 🇬🇧
Royal Marsden - Surrey, Sutton, England, United Kingdom
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 30
- Registration Number
- NCT00441168
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2020-02-19
- Target Recruit Count
- 31
- Registration Number
- NCT00440726
- Locations
- 🇨🇦
Sick Kids, Toronto, Ontario, Canada
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 331
- Registration Number
- NCT00440765
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.